Sensus Healthcare (5TX) AI Stock Analysis

2 Followers

Sensus Healthcare

(Frankfurt:5TX)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low leverageMinimal debt reduces financial risk and preserves flexibility while the company works through operating losses. A lightly levered balance sheet can support continued investment in commercialization and limit interest burdens, although it does not by itself restore profitability.

Negative Factors

Sharp operating deteriorationThe combination of declining revenue and deeply negative margins indicates that current scale is insufficient to cover the company’s cost base. Persistent operating deterioration weakens earnings power and makes a durable recovery dependent on materially better placements, utilization, or cost structure.

Sensus Healthcare (5TX) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 56.14M
Dividend Yield: ―
Average Volume (3M): 992
Price to Earnings (P/E): -3.6
Beta (1Y): -0.06
Revenue Growth: -56.73%
EPS Growth: -1548.68%
Country: Germany
Employees: 60
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Sensus Healthcare Business Overview & Revenue Model

Company Description

Sensus Healthcare, Inc. operates as a medical technology enterprise, manufacturing and distributing radiation therapy apparatuses to medical institutions across the globe. The company's portfolio leverages superficial radiation therapy (SRT), a cutti...

Sensus Healthcare Earnings Call Summary

Earnings Call Date:Aug 13, 2026(Q2-2026)|% Change Since:2.96%|Next Earnings Date:Nov 12, 2026

Earnings Call SentimentNegative

The call contained mixed operational positives — a strengthened pipeline, broader customer interest driven by new CPT codes, increasing Sensus Link adoption, and a clarified path for the eight delayed units to contribute to Q3 revenue. However, these commercial positives were overshadowed by steep year-over-year financial deterioration: a ~68.5% revenue decline, a significantly larger GAAP net loss ($8.7M vs $1.0M prior year) including a $5.7M valuation allowance, worsening adjusted EBITDA, declining other income, and inventory build with lower cash. Given the material financial setbacks in the quarter despite constructive commercial momentum and an expected H2 recovery, the net picture is negative.

Positive Updates

Pipeline and Commercial Momentum Strengthened

Management reports a materially stronger commercial pipeline in H2 2026 driven by physician education around new CPT codes, increased inbound interest, and engagement with larger physician groups and health systems. They stated the pipeline includes both new customers and multi-location opportunities that could drive recurring and scalable adoption.

Negative Updates

Sharp Revenue Decline

Revenue fell to $2.3M in Q2 2026 from $7.3M in Q2 2025 — a decrease of approximately $5.0M or ~68.5% year-over-year, driven primarily by fewer units sold (11 units vs 19 units prior-year).

Company Guidance

The guidance emphasized a stronger second half driven by conversion of a beefed-up pipeline and recognition of eight units (previously delayed by financing) that moved revenue into Q3; management noted Q2 revenue was $2.3M (vs. $7.3M a year ago) on 11 units sold (would have been 19), following 14 units in Q1, and said those eight units carry an ASP near $250K each. Key Q2 metrics: cost of sales $1.5M, gross profit ~$0.8M and gross margin 34.8%, G&A $1.8M, selling & marketing $1.1M, R&D $1.1M, adjusted EBITDA -$3.0M, net loss $8.7M (-$0.53/share) including a $5.7M deferred tax valuation allowance, cash $15.2M (down from $18.3M), inventory $18.4M, and no outstanding revolving borrowings; management expects continued mix of ~50/50 recurring (rentals/Fair Deal) and outright purchases, rising Sensus Link activations, and international growth (notably Australia/APAC) with the company focused on converting opportunities to drive improved H2 performance.

Sensus Healthcare Risk Analysis

Sensus Healthcare disclosed 24 risk factors in its most recent earnings report. Sensus Healthcare reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Sensus Healthcare Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:5TX against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PEN	67Neutral	$12.67B	80.63	10.44%	―	16.98%	-5.62%
INMD	58Neutral	$763.32M	10.98	11.80%	―	2.50%	-43.86%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IRIX	46Neutral	$12.30M	-3.21	-78.94%	―	3.68%	36.91%
NNOX	44Neutral	$29.40M	-0.21	-94.35%	―	31.52%	-89.07%
ARAY	41Neutral	$9.57M	-0.55	-36.60%	―	-12.50%	5.33%

* Healthcare Sector Average

Performance Comparison

DE:5TX and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:5TX	Sensus Healthcare, Inc.	2.78	-1.08	-27.98%
ARAY	Accuray Incorporated	3.20	-41.20	-92.79%
IRIX	Iridex	0.65	-0.24	-26.63%
PEN	Penumbra Inc.	321.72	42.98	15.42%
INMD	Inmode	13.73	-0.57	-3.99%
NNOX	Nano-X Imaging Ltd.	0.36	-2.56	-87.57%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Sensus Healthcare AI Stock Analysis